DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Mesothelioma” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the mesothelioma market, comprising
key pipeline and marketed drugs, clinical trials, upcoming and
regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals, as well as presenting
drug-specific revenue forecasts
Key Takeaways
-
The report estimates that in 2017, there were 18,900 incident cases of
mesothelioma in adults aged 45 years and older worldwide, and
forecaststhat number to increase to 22,690 incident cases by 2026. -
Oceania is estimated to have the highest disease incidence (2.85 per
100,000 males, and 0.50 per 100,000 females), while Latin America and
the Caribbean has the lowest incidence (0.29 per 100,000 males, and
0.17 per 100,000 females). -
The approved drugs in the mesothelioma space target thymidylate
synthase and dihydrofolate reductase. Both of the approved drugs are
administered via the intravenous route. -
The majority of industry-sponsored drugs in active clinical
development for mesothelioma are in Phase II. Therapies in the
mesothelioma space focus on a wide variety of targets. The majority of
drugs in development for mesothelioma are administered via the
intravenous route, with the remainder being intramuscular, oral,
intratumoral, and subcutaneous formulations. -
High-impact upcoming events in the mesothelioma space comprise topline
Phase III trial results for Zeltherva, and topline Phase II trial
results for Zepsyre. -
The overall likelihood of approval of a Phase I mesothelioma asset is
5.6%, and the average probability a drug advances from Phase III is
33.3%. Drugs, on average, take 14.7 years from Phase I to approval,
compared to 9.2 years in the overall oncology space. -
There were seven licensing and asset acquisition deals involving
mesothelioma drugs during 2014-18. The $475m licensing agreement
signed in 2017, between Calithera Biosciences and Incyte, to research,
develop, and commercialize Calithera’s CB1158, was the largest deal
during the period. -
The clinical trials distribution across Phase I-IV indicates that the
vast majority of trials have been in the early and mid-phases of
development, with 95% of trials in Phase I-II and only 5% in Phase
III-IV. -
The US has a substantial lead in the number of mesothelioma clinical
trials globally. The UK leads the major EU markets, while Japan has
the top spot in Asia. -
Clinical trial activity in the mesothelioma space is dominated by
completed trials. Eli Lilly has the highest number of completed
clinical trials for mesothelioma, with 42 trials. -
Eli Lilly leads industry sponsors with the highest number of clinical
trials for mesothelioma
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
Surgery
Chemotherapy
Radiotherapy
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
SEL-403 for Mesothelioma (October 17, 2018)
Tazemetostat for Mesothelioma (September 24, 2018)
Tazemetostat for Mesothelioma (April 23, 2018)
BAY 94-9343 for Mesothelioma (July 21, 2017)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/ndx0u4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs